Meta-analysis of the efficacy-indicator secondary endpoint in the three clinical trials. (A): percentage of participants with at least a 50% reduction from baseline in monthly migraine days. (B): the change from baseline in monthly acute migraine-specific medication treatment days (70 mg versus placebo). (C): the change from baseline in monthly acute migraine-specific medication treatment days (140 mg versus placebo)